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OBJECTIVE—Insulin-mediated suppression of hepatic glucose
production (HGP) is associated with sensitive intracellular sig-
naling and molecular inhibition of gluconeogenic (GNG) enzyme
mRNA expression. We determined, for the ﬁrst time, the time
course and relevance (to metabolic ﬂux) of these molecular
events during physiological hyperinsulinemia in vivo in a large
animal model.
RESEARCH DESIGN AND METHODS—24 h fasted dogs were
infused with somatostatin, while insulin (basal or 8 basal) and
glucagon (basal) were replaced intraportally. Euglycemia was
maintained and glucose metabolism was assessed using tracer,
2H2O, and arterio-venous difference techniques. Studies were
terminated at different time points to evaluate insulin signaling
and enzyme regulation in the liver.
RESULTS—Hyperinsulinemia reduced HGP due to a rapid tran-
sition from net glycogen breakdown to synthesis, which was
associated with an increase in glycogen synthase and a decrease
in glycogen phosphorylase activity. Thirty minutes of hyperinsu-
linemia resulted in an increase in phospho-FOXO1, a decrease in
GNG enzyme mRNA expression, an increase in F2,6P2, a de-
crease in fat oxidation, and a transient decrease in net GNG ﬂux.
Net GNG ﬂux was restored to basal by 4 h, despite a substantial
reduction in PEPCK protein, as gluconeogenically-derived car-
bon was redirected from lactate efﬂux to glycogen deposition.
CONCLUSIONS—In response to acute physiologic hyperinsu-
linemia, 1) HGP is suppressed primarily through modulation of
glycogen metabolism; 2) a transient reduction in net GNG ﬂux
occurs and is explained by increased glycolysis resulting from
increased F2,6P2 and decreased fat oxidation; and 3) net GNG
ﬂux is not ultimately inhibited by the rise in insulin, despite
eventual reduction in PEPCK protein, supporting the concept
that PEPCK has poor control strength over the gluconeogenic
pathway in vivo. Diabetes 59:1302–1311, 2010
I
nsulin acutely inhibits hepatic glucose production
(HGP) in vivo by inhibiting glucose formation from
both glycogenolysis and gluconeogenesis (GNG).
Metabolic data in dogs and humans indicate that
glycogenolytic ﬂux is sensitively inhibited by physiological
hyperinsulinemia, but gluconeogenic ﬂux is not (1–8).
These data suggest that insulin inhibits the gluconeogenic
component of glucose production by diverting gluconeo-
genically derived glucose-6-phosphate (G6P) to glycogen,
rather than suppressing gluconeogenic formation of G6P
(GNG ﬂux-to-G6P). Conversely, data from in vitro studies
and in vivo studies in rodents have shown that insulin-
mediated mechanisms inhibit both the glycogenolytic and
gluconeogenic pathways at the enzymatic level. Insulin
inhibits glycogen phosphorylase and stimulates glycogen
synthase, facilitating the transition of the liver from glyco-
gen breakdown to synthesis (9). Insulin also inhibits the
gene expression of PEPCK and G6Pase, enzymes often
described as rate-limiting in the GNG pathway. The CREB-
regulated transcription coactivator-2 (CRTC2) drives the
expression of PGC1, and PGC1 interacts with FOXO1 to
promote GNG gene expression (10–12). Hepatic insulin
action results in the phosphorylation of CRTC2 and
FOXO1, which excludes these proteins from the nucleus
and reduces PEPCK and G6Pase gene expression (10–12).
Recently, it has been suggested that insulin action in the
brain also plays a role in suppressing GNG (13–15). It has
been proposed that a rise in hypothalamic insulin modiﬁes
vagal input to the liver, leading to the phosphorylation of
STAT3, which then inhibits GNG gene expression (13).
Since the biochemistry of GNG regulation has largely
been established in rodent systems, the question arises as
to whether it is applicable to large animals and humans.
The molecular regulation of GNG by insulin in vivo has not
been well characterized in humans due to the invasiveness
of sampling human liver and the inaccessibility of the
portal vein. The canine model offers the experimental
opportunity to deliver insulin via the portal vein, to
measure net balance of gluconeogenic substrates and
glucose across the liver, and to obtain liver tissue for
molecular characterization in a model that has proven to
have high translational value to humans (16). Our aim was
to characterize, for the ﬁrst time, the time course of
relevant insulin-mediated molecular events during the
suppression of HGP by selective physiological (approxi-
mately eightfold) hyperinsulinemia in the conscious dog
and to correlate these molecular changes with alterations
in metabolic ﬂux. The pancreatic clamp technique was
used to isolate the effects of a selective rise in insulin in
the presence of euglycemia and basal glucagon. Dogs were
fasted for 24 h to create a situation in which the basal rates
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those in the overnight fasted human. Studies were ended
after different durations of hyperinsulinemia, at which
time liver samples were obtained for the measurement of
molecular markers. Control animals were not exposed to
elevated insulin but were otherwise treated the same.
RESEARCH DESIGN AND METHODS
Animal care and surgical procedures. Adult dogs of either sex, with a mean
weight of 21.9  0.2 kg at time of study, were housed and fed as described
previously (5) and then studied after a 24 h fast. The surgical facility met the
standards published by the American Association for the Accreditation of
Laboratory Animal Care, and the protocols met the approval of the Vanderbilt
University Medical Center Animal Care Committee. Two weeks before exper-
imentation, all dogs underwent a laparotomy to implant sampling catheters
into the femoral artery, the portal vein, and the hepatic vein, to place infusion
catheters in the splenic and jujenal veins, and to place ultrasonic ﬂow probes
(Transonic Systems, Ithaca, NY) around the hepatic artery and the portal vein,
as described previously (5). All dogs were healthy, as indicated by 1)
leukocyte count 18,000/mm
3, 2) hematocrit 35%, and 3) good appetite and
normal stools.
Experimental design. Each study consisted of an equilibration (150 to 30
min), a basal (30 to 0 min), and an experimental period (0.5, 1, 2, or 4 h). At
150 min, salinized
2H2O (3 ml/kg; Sigma) was administered intravenously in
a subset of animals in each group (n  3 control and n  5 experimental) to
achieve 0.55% enrichment of body water. All animals were carefully moni-
tored during the experiments, and no adverse effects of
2H2O administration
were detected. At 120 min, a priming dose of [3-
3H]glucose (35 	Ci) was
given, followed by a constant infusion of [3-
3H]glucose (0.35 	Ci/min). At the
beginning of the experimental period, somatostatin was infused peripherally
(0.8 	g  kg
1  min
1; Bachem, Torrance, CA) to inhibit the endocrine
pancreas, and glucagon was replaced intraportally in basal amounts (0.57 ng 
kg
1  min
1; Lilly, Indianapolis, IN). In the control group (n  7), insulin
(Lilly) was infused intraportally at rates matched to basal levels (240 	U 
kg
1  min
1). In the experimental group (n  20), insulin was infused
intraportally at a rate (2,000 	U  kg
1  min
1) that produced an eightfold rise
from baseline. In all studies, glucose was infused peripherally as required to
maintain euglycemia. In the control group, subsets of experiments were
terminated either after2h( n  4 )o r4h( n  3). In the experimental group,
a subset of experiments were terminated after 0.5 h (n  5 ) ,1h( n  4 ) ,2h
(n  6 ) ,a n d4h( n  5). Immediately after obtaining the ﬁnal blood sample,
each animal was anesthetized with pentobarbital and a laparotomy was
performed. The hormone and glucose infusions were continued while liver
sections from three separate lobes were freeze-clamped in situ and subse-
quently stored at 70°C. Liver biopsies were obtained within 3 min of the ﬁnal
blood sample time. Initial molecular analysis veriﬁed that there were minimal
differences in cellular signals between lobes, and as a result, the molecular
data reported for all animals were generated from analysis of liver lobe 2.
There were no differences between markers assessed in control samples taken
after 2 or4ho fbasal insulinemia; thus, the molecular data reported for the
control group reﬂect pooled data from all control animals.
Metabolite analysis. Hematocrit levels, glucose, glucagon, insulin, cortisol,
and nonesteriﬁed fatty acid (NEFA) levels in plasma and alanine, glycine,
serine, threonine, lactate, glutamine, glutamate, glycerol, and 
-hydroxybu-
tyrate concentrations in blood were determined using standard procedures as
previously described (5).
Molecular analysis. RNA extraction, cDNA synthesis, real-time PCR, SDS-
PAGE, and Western blotting were performed using standard methods (17).
Fructose-2,6-bisphosphate (F2,6P2) concentration and enzyme activities of
pyruvate kinase, G6Pase, glycogen synthase, and glycogen phosphorylase
were assessed using established methods (18–22).
Preparation of monoacetone glucose and
2H NMR (nuclear magnetic
resonance) spectroscopy. Whole-body GNG and glycogenolysis were cal-
culated using the
2H2O method combined with nuclear magnetic resonance
(NMR) analysis as previously described (23). NMR spectra were generated
independently for each animal. Brieﬂy, 10-ml plasma samples were deprotein-
ized and lyophilized. To convert plasma glucose to monoacetone glucose, the
dried residue was suspended in 5.0 ml acetone containing 200 	lH 2SO4. The
suspension was mixed for4ha troom temperature. After addition of 5 ml H2O,
pH was adjusted to 2 with drop-wise addition of 1.5 mol/l Na2CO3, and the
sample was mixed for 24 h at room temperature. The pH was then further
increased to 8 using Na2CO3, and the sample was dried. Monoacetone glucose
was extracted (three to four times) by addition of 3 ml hot ethyl acetate. Ethyl
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FIG. 1. Arterial plasma insulin (A), hepatic sinusoidal plasma insulin (B), arterial plasma glucagon (C), and hepatic sinusoidal plasma glucagon
concentrations (D) in 24 h fasted conscious dogs during the basal (30 to 0 min) and experimental (0–240 min) periods. Data are means  SEM;
n  7 in control (CTR) and n  20 in 8 insulin (8X INS) groups. *P < 0.05 vs. CTR group; †P < 0.05 vs. basal period.
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diabetes.diabetesjournals.org DIABETES, VOL. 59, JUNE 2010 1303acetate was removed via vacuum evaporation, and monoacetone glucose was
further puriﬁed by passage through a solid-phase extraction tube using ethyl
acetate as eluant. The efﬂuent was freeze-dried and stored before NMR
analysis.
NMR spectra for monoacetone glucose (dissolved in 100% acetonitrile)
were acquired using a 14.0 T Bruker magnet equipped with a Bruker AV-III
console operating at 92.12 MHz for
2H. All spectra were acquired in 3-mm NMR
tubes using a Bruker 5-mm TCI cryogenically cooled NMR probe. Chemical
shifts were referenced internally to CD3CN (1.98 ppm). For 1D
2H NMR,
typical experimental conditions included 2K data points, 20 ppm sweep width,
a recycle delay of 0.5 s, and 12–25K scans, depending on sample concentra-
tion. Data were processed using TOPSPIN software provided by Bruker
Biospin. Data analysis used an automated program for integration of the
2H
NMR spectra ensuring consistent and reproducible integration areas for all
acquired spectra.
Calculations. We determined whole-body GNG and glycogenolysis using the
following calculations: gluconeogenesis  Ra  C5/C2 and glycogenolysis 
Ra  gluconeogenesis. Ra represents tracer-derived endogenous glucose
production calculated using the two-compartment circulatory model de-
scribed by Mari et al. (24), and C5/C2 represents the ratio of deuterium
enrichment at the respective carbon positions of glucose.
Net hepatic substrate balances were calculated with the arterio-venous
(A-V) difference method using the formula: net hepatic substrate balance 
Loadout  Loadin, where Loadout  [H]  HF and Loadin  [A]  AF  [P] 
PF. [A], [P], and [H] represent substrate concentrations in femoral artery,
portal vein, and hepatic vein blood or plasma, respectively, and AF, PF, and
HF represent blood or plasma ﬂow (as measured using ultrasonic ﬂow probes)
through the hepatic artery, the portal vein, and the hepatic vein, respectively.
With this calculation, positive values reﬂect net hepatic production and
negative values represent net hepatic uptake. Plasma glucose values were
multiplied by 0.73 to convert them to blood glucose values as previously
validated (25). Net hepatic fractional extraction was calculated by dividing net
hepatic substrate balance by hepatic substrate load. The approximate insulin
and glucose levels in plasma entering the liver sinusoids were calculated using
the formula [A]  %AF  [P]  %PF, where [A] and [P] represent arterial and
portal vein concentrations, respectively, and %AF and %PF are the respective
fractional contributions of arterial and portal blood ﬂow to total hepatic blood
ﬂow.
We estimated net hepatic gluconeogenic (NHGNG) ﬂux by subtracting
glycolytic ﬂux from gluconeogenic ﬂux-to-G6P. GNG ﬂux-to-G6P was deter-
mined by taking the sum of net hepatic uptake rates of gluconeogenic
precursors (alanine, glycine, serine, threonine, glutamine, glutamate, glycerol,
lactate, and pyruvate) and dividing by 2 to account for the incorporation of
two three-carbon precursors into one six-carbon glucose molecule. Glycolytic
ﬂux was estimated by taking the sum of the net hepatic output rates (when
present) of the gluconeogenic substrates noted above (in glucose equivalents)
and hepatic glucose oxidation (assumed to be 0.2  0.1 mg  kg
1  min
1). We
have veriﬁed that glucose oxidation remains at a low and constant rate across
wide variations in physiological parameters (26,27). Positive NHGNG ﬂux
reﬂects net GNG ﬂux-to-G6P, whereas negative values represent net glycolytic
ﬂux to CO2 or lactate. Net hepatic glycogenolytic ﬂux was estimated by
subtracting NHGNG ﬂux from net hepatic glucose balance. Positive net
hepatic glycogenolytic ﬂux reﬂects net glycogen breakdown, and negative
values represent net glycogen synthesis.
There are several assumptions required when using the A-V difference
technique in assessment of GNG ﬂux-to-G6P. For example, this method
assumes that substrate ﬂux is unidirectional at any given point in time. There
is negligible production of gluconeogenic amino acids or glycerol by the liver,
so for these substrates, the compromise is of little consequence. Predomi-
nantly gluconeogenic periportal and glycolytic perivenous hepatocytes could
simultaneously take up and release lactate, respectively, which could lead to
an underestimation of GNG ﬂux-to-G6P. It must be noted that simultaneous
lactate uptake and release would not, however, affect our estimation of
NHGNG ﬂux or net hepatic glycogenolytic ﬂux. NHGNG ﬂux and net hepatic
glycogenolytic ﬂux estimations are subject to error to the degree that
intrahepatic GNG amino acids contribute to the formation of G6P. The method
also assumes 100% conversion of the GNG amino acids taken up by the liver
into G6P (they are not oxidized or used in the synthesis of proteins). Errors
arising from the assumptions are difﬁcult to assess but appear to be minimal,
as simultaneous assessment of GNG ﬂux using the A-V difference technique
and other independent methods (that are not subject to the same assump-
tions) yielded similar estimates of GNG ﬂux (5,28).
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FIG. 2. Arterial plasma NEFA levels (A), net hepatic NEFA uptake (B), arterial plasma -hydroxybutyrate levels (C), and net hepatic
-hydroxybutyrate production (D) in 24 h fasted conscious dogs during the basal (30 to 0 min) and experimental (0–240 min) periods. Data are
means  SEM; n  7 in control (CTR) and n  20 in 8 insulin (8X INS) groups. *P < 0.05 vs. CTR group; †P < 0.05 vs. basal period.
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1304 DIABETES, VOL. 59, JUNE 2010 diabetes.diabetesjournals.orgStatistical analysis. Statistical comparisons were carried out using two-way
repeated-measure ANOVA (group  time) (SigmaStat). One-way ANOVA
comparison tests were used post hoc when signiﬁcant F ratios were obtained.
Signiﬁcance was determined as P  0.05.
RESULTS
Hormone levels. In the control group, insulin was re-
placed at basal levels, whereas both arterial and hepatic
sinusoidal insulin levels increased eightfold in the experi-
mental group (Fig. 1A and B). Arterial and hepatic sinu-
soidal glucagon levels were clamped at basal values in all
animals (Fig. 1C and D). Arterial cortisol levels were also
basal in all animals (data not shown).
Fat metabolism. Arterial NEFA levels tended to decline
slowly in the control group, resulting in a modest reduc-
tion by 240 min (Fig. 2A). Conversely, there was a rapid
and marked decrease in arterial NEFA levels (61 and 96%
at 30 and 240 min, respectively) in response to hyperinsu-
linemia. Consistent with these data, there were minimal
changes in net hepatic NEFA uptake (Fig. 2B) and oxida-
tion (Fig. 2D) in control animals, but rapid and substantial
suppression of these parameters in the hyperinsulinemic
group.
Gluconeogenic precursor metabolism. In control ani-
mals, there was no signiﬁcant change in arterial blood
lactate levels (Fig. 3A) or net hepatic lactate balance (Fig.
3B) over time. Conversely, hyperinsulinemia caused a
transient increase in arterial blood lactate levels and a
switch from net hepatic lactate uptake to net hepatic
lactate output that was evident between 30 and 120 min.
By 240 min, net hepatic lactate uptake had returned to
baseline rates.
While arterial plasma glycerol levels and net hepatic
glycerol uptake did not change signiﬁcantly in the control
group, both of these parameters decreased rapidly (50 and
61% by 30 min) in response to hyperinsulinemia and
remained suppressed for the duration of the study (sup-
plementary Table 1, which can be found in an online
appendix at http://diabetes.diabetesjournals.org/cgi/
content/full/db09-1625/DC1). There were no signiﬁcant
changes over time in arterial blood alanine levels, net
hepatic fractional extraction of alanine, or net hepatic
alanine balance in the control group (supplementary Table
1). Conversely, blood alanine concentrations eventually
fell (40 and 54% by 120 and 240 min, respectively) in
response to hyperinsulinemia. Net hepatic alanine uptake
rates did not change over time in the hyperinsulinemic
group despite the decreased arterial levels because net
hepatic fractional extraction of alanine increased (1.8-fold
by 240 min). Similar trends were observed for serine,
glycine, threonine, glutamate, and glutamine (data not
shown). Thus, in the control animals, the summed blood
level, net hepatic fractional extraction, and net hepatic
uptake of gluconeogenic amino acids failed to change.
Hyperinsulinemia, on the other hand, resulted in a gradual
decrease in amino acid levels in blood (32% after 240 min),
an increase (56% by 240 min) in their net hepatic fractional
extraction, and no change in their net hepatic uptake
(supplementary Table 1).
Glucose, glycogenolytic, and gluceoneogenic ﬂux
rates. Euglycemia was maintained in all animals (Fig. 4A),
requiring glucose infusion rates of 0.2  0.1 and 13.3  0.9
mg  kg
1  min
1 in the control and hyperinsulinemic
groups, respectively, during the last hour of study. In the
basal period, net hepatic glucose output was similar (2.0
mg  kg
1  min
1) in both groups. Net hepatic glucose
output declined minimally (17%) over time in the control
group (Fig. 4B), whereas in the hyperinsulinemic group, it
rapidly declined (75% by 30 min) and was completely
inhibited by 60 min, after which the liver switched to net
glucose uptake (0.8  0.1 mg  kg
1  min
1 at 240 min).
Net hepatic glycogenolytic ﬂux fell slightly (25%, NS)
over time in the control group but was rapidly suppressed
(43% reduction by 30 min) by hyperinsulinemia, being
completely inhibited by 60 min. By the end of the study,
the liver had switched to a state of net hepatic glycogen
synthesis (Fig. 4C). NHGNG ﬂux did not change from basal
in the control group but was transiently decreased in
response to hyperinsulinemia so that the liver switched to
net glycolysis from 30 to 90 min (Fig. 4D). By the end of
the study, NHGNG ﬂux had returned to near-basal. The
suppression of net hepatic glucose output by hyperinsu-
linemia was conﬁrmed by reduced tracer-derived endoge-
nous glucose production (Fig. 5A) and was indicative of
the complete suppression (at 240 min) of whole-body GNG
(Fig. 5B) and glycogenolysis (Fig. 5C), as determined using
the
2H2O technique.
Molecular effects of insulin. The time course of intra-
cellular insulin-regulated events was assessed in hepatic
biopsies obtained from the hyperinsulinemic group and
expressed relative to the data obtained from control
animals. In response to hyperinsulinemia, Akt and GSK-3

phosphorylation increased approximately twofold and ap-
proximately threefold at 30 and 60 min, respectively,
relative to the control group (Fig. 6A). The level of
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FIG. 3. Arterial blood lactate concentrations (A) and net hepatic
lactate uptake (B) in 24 h fasted conscious dogs during the basal (30
to 0 min) and experimental (0–240 min) periods. Data are means 
SEM; n  7 in control (CTR) and n  20 in 8 insulin (8X INS) groups.
*P < 0.05 vs. CTR group; †P < 0.05 vs. basal period.
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(20%, NS) by 60 min and was maximally reduced (45%)
for the last 120 min of the study (Fig. 6B). The glycogen
synthase activity ratio was elevated twofold from 30 min
on (Fig. 6C), whereas the glycogen phosphorylase activity
ratio was decreased 40% (Fig. 6D).
Hyperinsulinemia caused a twofold increase in FOXO1
phosphorylation (and 52% decrease in nuclear FOXO1
content) by 30 min (Fig. 7A). FOXO1 levels in nuclear-
enriched fractions eventually decreased by 95% in the
hyperinsulinemic group. CRTC2 phosphorylation in-
creased approximately twofold, and PGC1 protein levels
decreased (43%) by 120 min (Fig. 7B). STAT3 phosphory-
lation increased approximately twofold, but it took 240
min before a signiﬁcant change was observed (Fig. 7C).
Hyperinsulinemia resulted in rapid (45–50% by 30 min) and
marked (80–90% by 240 min) decreases in PEPCK and
G6Pase mRNA (Fig. 7D). The PEPCK protein level did not
change during the ﬁrst hour of hyperinsulinemia but was
reduced 31 and 48% at 120 and 240 min, respectively (Fig.
7E), whereas G6Pase activity was modestly reduced at 240
min (30%, NS, Fig. 7F).
Glucokinase opposes the action of G6Pase. Hyperinsu-
linemia stimulated 3- and 11-fold increases in glucokinase
mRNA at 30 and 240 min, respectively, whereas glucoki-
nase protein was not elevated until 120 min (twofold) and
was elevated threefold by 240 min (Fig. 8A). Hepatic
F2,6P2 concentration and pyruvate kinase activity, both of
which stimulate glycolysis and inhibit GNG, were also
assessed. F2,6P2 increased approximately threefold by 30
min and ﬁvefold by 60 min in response to hyperinsulinemia
and remained elevated for the duration of the experiment
(Fig. 8B). Pyruvate kinase activity was increased 1.7-fold
for the last 120 min of hyperinsulinemia (Fig. 8C).
DISCUSSION
The distinction between hepatic gluconeogenesis (GNG;
liver production of glucose derived from GNG precursors)
and gluconeogenic formation of G6P is crucial to the
interpretation of insulin’s effect on HGP. In the present
study, a physiological eightfold rise in portally infused
insulin rapidly inhibited HGP in 24 h fasted dogs. Thus,
glycogenolysis and gluconeogenesis, classically deﬁned as
hepatic output of glucose derived from the glycogenolytic
and gluconeogenic pathways, were both sharply reduced.
However, the inhibition of NHGNG ﬂux was transient, so
that after 240 min, it was unchanged from baseline. Thus,
by the end of the study, insulin had reduced the GNG
fraction of HGP to zero without affecting the net gluconeo-
genic rate of G6P formation, but rather by promoting the
deposition of G6P in glycogen. Net hepatic glycogenolytic
ﬂux was strongly inhibited by 30 min and completely
suppressed by 60 min, and thereafter the liver exhibited
net glycogen synthesis. The metabolic conversion of the
liver to an organ of net glycogen storage correlated with
insulin’s rapid and reciprocal regulation of glycogen phos-
phorylase (2) and glycogen synthase (1). Insulin even-
tually (120 min) brought about an increase in glucokinase
protein and thus glucokinase may have played a role in
facilitating glucose entry and in sustaining the maximal
rate of glycogen synthesis.
Hyperinsulinemia resulted in substantial decreases (40–
50%) in PEPCK and G6Pase mRNA at 30 min, which
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tion and preceded changes in other key regulatory loci
(CRTC2, PGC1, STAT3). PEPCK mRNA was suppressed
by 80% at 2 h, before any signiﬁcant increases in STAT3
phosphorylation. STAT3 inhibits GNG mRNA expression
(29), and in mice, it has been suggested that STAT3 is the
hepatic effector for insulin-brain-liver signaling required
for suppression of GNG in vivo (13). Regardless of the
validity of this concept, which is doubted by some (30), we
show here that the repression of GNG mRNA expression is
associated with FOXO1 phosphorylation and occurs be-
fore STAT3-mediated regulation.
While we veriﬁed that the rodent-derived model of
insulin-mediated suppression of GNG gene expression is
intact and applicable to large animals, these molecular
events did not affect the acute regulation of NHGNG ﬂux.
Hyperinsulinemia reduced NHGNG ﬂux (resulting in net
glycolysis) at 30 min, and this preceded functional changes
in gluconeogenic enzymes (PEPCK, G6Pase) or the acti-
vation of pyruvate kinase, which is considered to be a key
regulatory enzyme of glycolysis (31). On the other hand, it
correlated with an increase in hepatic F2,6P2 a n dad e -
crease in lipolysis and hepatic fat oxidation. This suggests
that hepatic F2,6P2 and hepatic fat oxidation have greater
regulatory strength over the insulin-mediated enhance-
ment of glycolysis in vivo than does pyruvate kinase.
Insulin stimulates the dephosphorylation of 6-phospho-
fructokinase-2 (PFK-2)/fructose-2,6-bisphosphatase (FB-
Pase-2), increasing PFK-2 activity and inhibiting FBPase-2
activity, the net of which increases the level of F2,6P2,a
metabolite that promotes glycolysis and inhibits GNG in
vitro (31). Oxidation of fat by the liver generates intrahe-
patic metabolites that inhibit glycolysis and promote GNG.
Insulin-mediated suppression of lipolysis therefore results
in the removal of these cues (32). Indeed, after 30 min,
glycolysis was enhanced and glycogenolytically derived
carbon entered glycolysis and exited the liver in the form
of lactate rather than glucose. As a consequence, the liver
switched from a state of net lactate consumption (using
lactate as a GNG precursor) to an organ of net lactate
production.
We previously observed that selective peripheral hyper-
insulinemia (with no change in insulin at the liver or,
presumably, F2,6P2) suppressed HGP due to a reduction in
NHGNG ﬂux, and the time course of this suppression
correlated with decreased lipolysis and increased net
hepatic lactate output (33). When arterial NEFA levels
were clamped at basal levels with intralipid infusion,
peripheral hyperinsulinemia could not modify hepatic
glycolysis, net hepatic lactate balance, or NHGNG ﬂux
(33). In another study, selective hepatic hyperinsulinemia
(and, presumably, increased F2,6P2, with no change in
arterial insulin) suppressed HGP entirely by inhibiting
glycogenolysis, without altering NHGNG ﬂux (34). Taken
together, these studies (33,34) suggest that acute regula-
tion of NHGNG ﬂux by insulin is caused by the suppres-
sion of lipolysis and may be independent of changes in
F2,6P2. It must be noted that F2,6P2 was not assessed in
these earlier studies (33,34), whereas it was in the present
study, so we cannot be certain which (increased F2,6P2 or
decreased lipolysis) was the dominant factor mediating
the transient decrease in NHGNG ﬂux.
By 240 min, NHGNG ﬂux had returned to its baseline
value despite an 50% reduction in PEPCK protein and
persisting conditions that favored glycolysis (increased
F2,6P2, increased pyruvate kinase activity, and decreased
hepatic fat oxidation). Theoretically, the transient de-
crease in NHGNG could have reﬂected enhanced glyco-
lytic ﬂux, decreased GNG ﬂux-to-G6P, or both. Our
observation that GNG ﬂux-to-G6P was basal at 240 min
suggests that the transient change in NHGNG ﬂux was due
to an alteration in glycolysis (supplementary Fig. 1). GNG
ﬂux-to-G6P remains active and important to glycogen
deposition in the postprandial state in a variety of species,
suggesting that the pathway is insensitive to hyperinsulin-
emia (and insulin-mediated increased F2,6P2) in vivo (35–
39). Conversely, hyperinsulinemia (and the resulting
increased F2,6P2) has been shown to enhance glycolysis in
vivo, and this has been suggested to be a mechanism by
which insulin reduces HGP (40–42). The rebound in
NHGNG ﬂux likely resulted from the cessation of glycogen
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lytic pathway. This, in turn, caused the restoration of net
hepatic lactate uptake and the deposition of gluconeogeni-
cally derived carbon in glycogen. Thus, the complete
suppression of HGP observed after several hours of hyper-
insulinemia appears to have been a function of the switch
from net glycogenolysis to net glycogen synthesis, with
NHGNG ﬂux being unchanged.
The notion that insulin can inhibit GNG ﬂux-to-G6P is
based largely on experiments carried out using isolated
hepatocytes and perfused livers from rats (31). However,
these studies typically examined the process in the ab-
sence of many factors (hepatic glycogen, neural input, and
physiological concentrations of other hormones and cir-
culating fatty acids) that play important roles in the
regulation of HGP in vivo (16). For example, in mice, the
deletion of CRTC2 resulted in reduced PEPCK and G6Pase
gene expression in vitro and in vivo; however, while this
impaired glucagon-stimulated HGP in vitro, it did not alter
glucose metabolism in vivo (43). Additionally, insulin-
induced inhibition of glucose output from liver tissue in
vitro could reﬂect changes in glycogen synthesis and
glycolysis, as well as alteration in GNG ﬂux-to-G6P. Thus,
in vitro studies of GNG are limited in their ability to
characterize the physiologic regulation of the pathway in
vivo.
Based on recent rodent studies, it was concluded that
hyperinsulinemia in the brain inhibited HGP by reducing
GNG associated with inhibition of GNG gene expression
(13–15) and STAT3 phosphorylation (13). It is possible
that the sensitivity and mechanism of insulin-mediated
inhibition of HGP may be species-dependent. Rodents
have 5–10 the basal HGP rates of large animals, and they
exhaust liver glycogen stores after a fairly short fast,
whereas canines (and humans) have the capacity to main-
tain a signiﬁcant amount of liver glycogen after several
days of fasting (44,45). It is also possible that the drive to
maintain GNG ﬂux-to-G6P during hyperinsulinemia differs
between species. However, certain rodent studies have
shown that GNG ﬂux-to-G6P persists (with carbon redi-
rected to glycogen) during feeding (37,38), which contra-
dicts the notion that hyperinsulinemia can inhibit the
pathway. The sensitivity of GNG ﬂux-to-G6P to insulin
may also vary according to dose and fasting length; we
recently reported that 16-fold hyperinsulinemia could
suppress GNG ﬂux-to-G6P in prolonged fasted (60 h) dogs
in a manner that could not be explained by functional
changes in PEPCK (17). Thus, there is uncertainty regard-
ing the physiological and experimental circumstances
under which insulin-mediated suppression of GNG ﬂux-
to-G6P can be detected.
Several early studies in rats showed that selective
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PEPCK reduced GNG from gluconeogenesis precursors in
vitro and lowered blood glucose and the GNG fraction of
glycogen formation in vivo (38,46–48). These studies led
to the notion that PEPCK is a dominant point of control
in regulating GNG. However, these rat data may not be
entirely transferable to humans due to the aforemen-
tioned differences between species. Furthermore, the
complete inhibition of PEPCK activity achieved with
3-mercaptopicolinate is different from physiological in-
hibition of PEPCK protein by insulin, which, even after
4 h in our study, only reduced the protein by 50%. This
distinction is supported by a recent study using per-
fused livers from transgenic mice with large variations
in hepatic PEPCK enzyme (49). Data from Burgess et al.
(49) demonstrated that a 50% reduction in PEPCK
protein content was not associated with a signiﬁcant
decrease in ﬂux through PEPCK, whereas the complete
absence of PEPCK protein did inhibit the pathway.
Thus, our data support the notion that, under physio-
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strength over the process (49).
It is possible that GNG enzyme activity may exert a
higher degree of control on GNG in a chronic insulin-
resistant state, since rodent models of diabetes typically
display elevated HGP associated with increased PEPCK
and G6Pase mRNA (50–52). However, Samuel et al. (53)
recently showed that HGP and GNG were increased in two
rodent models of diabetes despite normal levels of hepatic
GNG enzyme mRNA. Furthermore, this group veriﬁed that
PEPCK and G6Pase mRNA levels were not increased in
human liver biopsies obtained from individuals with type 2
diabetes. While PEPCK may have high control strength on
other aspects of hepatic metabolism such as TCA cycle
ﬂux (49), the notion that PEPCK is rate-determining in the
GNG process appears to be inaccurate.
In summary, physiological hyperinsulinemia rapidly
suppressed HGP in the conscious dog, and after 4 h, this
inhibition was solely due to profound effects on glycogen
metabolism with no alteration in NHGNG or GNG ﬂux-to-
G6P. Canonical insulin-mediated signaling mechanisms
were rapidly activated, and the switch from glycogenolysis
to glycogen synthesis was associated with the activation of
glycogen synthase and inhibition of glycogen phosphory-
lase. Hyperinsulinemia led to the phosphorylation of
FOXO1 and suppression of PEPCK and G6Pase mRNA
levels, before alterations in other regulatory loci (CRTC2/
PGC1/STAT3). By 30 min, insulin increased hepatic
F2,6P2 and decreased hepatic fatty acid oxidation; these
factors stimulated glycolysis, resulting in net lactate pro-
duction and a transient reduction in NHGNG ﬂux. NHGNG
ﬂux returned to baseline (despite substantially reduced
PEPCK protein) by the end of the study as carbon was
redirected to glycogen synthesis. We conclude that acute
hyperinsulinemia regulates HGP through transient alter-
ations in glycolysis and persisting effects on glycogen
metabolism. Physiologic hyperinsulinemia has little or no
effect on gluconeogenic formation of G6P despite reduced
levels of PEPCK protein, indicating that PEPCK has little
control over the gluconeogenic pathway.
ACKNOWLEDGMENTS
This research was supported in part by National Institutes
of Health Grant R37-DK-18243 and the Diabetes Research
and Training Center Grant SP-60-AM20593. C.J.R. was
supported by an American Diabetes Association mentor-
based fellowship. A.D.C. was supported by the Jacquelyn
A. Turner and Dr. Dorothy J. Turner Chair in Diabetes
Research.
No other potential conﬂicts of interest relevant to this
article were reported.
We thank Dr. Masakazu Shiota, Dr. Rob Hall, Jon
Hastings, Angelina Penaloza, Wanda Snead, Patrick
Donahue, and Suzan Vaughan (Vanderbilt University) for
their excellent technical support. We are grateful to Dr.
Alex Lange (University of Minnesota) for providing re-
agents and expertise.
REFERENCES
1. Adkins A, Basu R, Persson M, Dicke B, Shah P, Vella A, Schwenk WF, Rizza
R. Higher insulin concentrations are required to suppress gluconeogenesis
than glycogenolysis in nondiabetic humans. Diabetes 2003;52:2213–2220
2. Boden G, Cheung P, Homko C. Effects of acute insulin excess and
deﬁciency on gluconeogenesis and glycogenolysis in type 1 diabetes.
Diabetes 2003;52:133–137
3. Boden G, Cheung P, Stein TP, Kresge K, Mozzoli M. FFA cause hepatic
insulin resistance by inhibiting insulin suppression of glycogenolysis. Am J
Physiol Endocrinol Metab 2002;283:E12–E19
4. Cherrington AD. Banting Lecture 1997. Control of glucose uptake and
release by the liver in vivo. Diabetes 1999;48:1198–1214
5. Edgerton DS, Cardin S, Emshwiller M, Neal D, Chandramouli V, Schumann
WC, Landau BR, Rossetti L, Cherrington AD. Small increases in insulin
inhibit hepatic glucose production solely caused by an effect on glycogen
metabolism. Diabetes 2001;50:1872–1882
6. Gastaldelli A, Toschi E, Pettiti M, Frascerra S, Quin ˜ones-Galvan A, Sironi
AM, Natali A, Ferrannini E. Effect of physiological hyperinsulinemia on
gluconeogenesis in nondiabetic subjects and in type 2 diabetic patients.
Diabetes 2001;50:1807–1812
7. Nuttall FQ, Ngo A, Gannon MC. Regulation of hepatic glucose production
0
4
8
12
16
CTR
CTR
30 60 120 240
R
e
l
a
t
i
v
e
 
a
b
u
n
d
a
n
c
e
GK mRNA
GK protein
8X Basal INS, min
A
B
C
0
4
8
12
30 60 120 240
F
2
,
6
P
2
 
(
n
m
o
l
/
g
w
w
)
0.0
0.2
0.4
0.6
CTR 30 60 120 240
P
K
 
a
c
t
i
v
i
t
y
 
(
U
/
m
g
 
p
r
o
t
e
i
n
)
*
*
*
*
*
*
*
*
*
FIG. 8. A: Relative glucokinase (GK) mRNA expression and protein
levels. B: Hepatic levels of F2,6P2 (expressed per gram wet weight,
gww). C: Hepatic pyruvate kinase (PK) activity. Histograms depict
mean values  SEM. *Signiﬁcantly different from the value for CTR,
P < 0.05.
TIME COURSE OF INSULIN ACTION
1310 DIABETES, VOL. 59, JUNE 2010 diabetes.diabetesjournals.organd the role of gluconeogenesis in humans: is the rate of gluconeogenesis
constant? Diabete Metab Res Rev 2008;24:438–458
8. Petersen KF, Laurent D, Rothman DL, Cline GW, Shulman GI. Mechanism
by which glucose and insulin inhibit net hepatic glycogenolysis in humans.
J Clin Invest 1998;101:1203–1209
9. Villar-Palasí C, Guinovart JJ. The role of glucose 6-phosphate in the control
of glycogen synthase. FASEB J 1997;11:544–558
10. Liu Y, Dentin R, Chen D, Hedrick S, Ravnskjaer K, Schenk S, Milne J,
Meyers DJ, Cole P, Yates J 3rd, Olefsky J, Guarente L, Montminy M. A
fasting inducible switch modulates gluconeogenesis via activator/coacti-
vator exchange. Nature 2008;456:269–273
11. Puigserver P, Rhee J, Donovan J, Walkey CJ, Yoon JC, Oriente F, Kitamura
Y, Altomonte J, Dong H, Accili D, Spiegelman BM. Insulin-regulated
hepatic gluconeogenesis through FOXO1-PGC-1alpha interaction. Nature
2003;423:550–555
12. Schilling MM, Oeser JK, Boustead JN, Flemming BP, O’Brien RM. Glucone-
ogenesis: re-evaluating the FOXO1-PGC-1alpha connection. Nature 2006;
443:E10–E11
13. Inoue H, Ogawa W, Asakawa A, Okamoto Y, Nishizawa A, Matsumoto M,
Teshigawara K, Matsuki Y, Watanabe E, Hiramatsu R, Notohara K,
Katayose K, Okamura H, Kahn CR, Noda T, Takeda K, Akira S, Inui A,
Kasuga M. Role of hepatic STAT3 in brain-insulin action on hepatic glucose
production. Cell Metab 2006;3:267–275
14. Obici S, Zhang BB, Karkanias G, Rossetti L. Hypothalamic insulin signaling
is required for inhibition of glucose production. Nat Med 2002;8:1376–1382
15. Pocai A, Lam TK, Gutierrez-Juarez R, Obici S, Schwartz GJ, Bryan J,
Aguilar-Bryan L, Rossetti L. Hypothalamic K(ATP) channels control he-
patic glucose production. Nature 2005;434:1026–1031
16. Cherrington AD, Moore MC, Sindelar DK, Edgerton DS. Insulin action on
the liver in vivo. Biochem Soc Trans 2007;35:1171–1174
17. Edgerton DS, Ramnanan CJ, Grueter CA, Johnson KM, Lautz M, Neal DW,
Williams PE, Cherrington AD. Effects of insulin on the metabolic control of
hepatic gluconeogenesis in vivo. Diabetes 2009;58:2766–2775
18. Arion WJ. Measurement of intactness of rat liver endoplasmic reticulum.
Methods Enzymol 1989;174:58–67
19. Guinovart JJ, Salavert A, Massague ´ J, Ciudad CJ, Salsas E, Itarte E.
Glycogen synthase: a new activity ratio assay expressing a high sensitivity
to the phosphorylation state. FEBS Lett 1979;106:284–288
20. Storey KB. Regulation of liver metabolism by enzyme phosphorylation
during mammalian hibernation. J Biol Chem 1987;262:1670–1673
21. Thomas JA, Schlender KK, Larner J. A rapid ﬁlter paper assay for
UDPglucose-glycogen glucosyltransferase, including an improved biosyn-
thesis of UDP-14C-glucose. Anal Biochem 1968;25:486–499
22. Wu C, Khan SA, Peng LJ, Lange AJ. Roles for fructose-2,6-bisphosphate in
the control of fuel metabolism: beyond its allosteric effects on glycolytic
and gluconeogenic enzymes. Adv Enzyme Regul 2006;46:72–88
23. Burgess SC, Hausler N, Merritt M, Jeffrey FM, Storey C, Milde A, Koshy S,
Lindner J, Magnuson MA, Malloy CR, Sherry AD. Impaired tricarboxylic
acid cycle activity in mouse livers lacking cytosolic phosphoenolpyruvate
carboxykinase. J Biol Chem 2004;279:48941–48949
24. Mari A, Stojanovska L, Proietto J, Thorburn AW. A circulatory model for
calculating non-steady-state glucose ﬂuxes: validation and comparison
with compartmental models. Comput Methods Programs Biomed 2003;71:
269–281
25. Edgerton DS, Cardin S, Pan C, Neal D, Farmer B, Converse M, Cherrington
AD. Effects of insulin deﬁciency or excess on hepatic gluconeogenic ﬂux
during glycogenolytic inhibition in the conscious dog. Diabetes 2002;51:
3151–3162
26. Moore MC, Satake S, Lautz M, Soleimanpour SA, Neal DW, Smith M,
Cherrington AD. Nonesteriﬁed fatty acids and hepatic glucose metabolism
in the conscious dog. Diabetes 2004;53:32–40
27. Satake S, Moore MC, Igawa K, Converse M, Farmer B, Neal DW, Cher-
rington AD. Direct and indirect effects of insulin on glucose uptake and
storage by the liver. Diabetes 2002;51:1663–1671
28. Goldstein RE, Rossetti L, Palmer BA, Liu R, Massillon D, Scott M, Neal D,
Williams P, Peeler B, Cherrington AD. Effects of fasting and glucocorti-
coids on hepatic gluconeogenesis assessed using two independent meth-
ods in vivo. Am J Physiol Endocrinol Metab 2002;283:E946–E957
29. Erion DM, Yonemitsu S, Nie Y, Nagai Y, Gillum MP, Hsiao JJ, Iwasaki T,
Stark R, Weismann D, Yu XX, Murray SF, Bhanot S, Monia BP, Horvath TL,
Gao Q, Samuel VT, Shulman GI. SirT1 knockdown in liver decreases basal
hepatic glucose production and increases hepatic insulin responsiveness
in diabetic rats. Proc Natl Acad SciUSA2009;106:11288–11293
30. Buettner C, Camacho RC. Hypothalamic control of hepatic glucose pro-
duction and its potential role in insulin resistance. Endocrinol Metab Clin
North Am 2008;37:825–840
31. Pilkis SJ, el-Maghrabi MR, Claus TH. Hormonal regulation of hepatic
gluconeogenesis and glycolysis. Annu Rev Biochem 1988;57:755–783
32. Girard J. Metabolic adaptations to change of nutrition at birth. Biol
Neonate 1990;58(Suppl. 1):3–15
33. Sindelar DK, Chu CA, Rohlie M, Neal DW, Swift LL, Cherrington AD. The
role of fatty acids in mediating the effects of peripheral insulin on hepatic
glucose production in the conscious dog. Diabetes 1997;46:187–196
34. Sindelar DK, Balcom JH, Chu CA, Neal DW, Cherrington AD. A comparison
of the effects of selective increases in peripheral or portal insulin on
hepatic glucose production in the conscious dog. Diabetes 1996;45:1594–
1604
35. Barrett EJ, Bevilacqua S, DeFronzo RA, Ferrannini E. Glycogen turnover
during refeeding in the postabsorptive dog: implications for the estimation
of glycogen formation using tracer methods. Metabolism 1994;43:285–292
36. Jin ES, Uyeda K, Kawaguchi T, Burgess SC, Malloy CR, Sherry AD.
Increased hepatic fructose 2,6-bisphosphate after an oral glucose load
does not affect gluconeogenesis. J Biol Chem 2003;278:28427–28433
37. Newgard CB, Moore SV, Foster DW, McGarry JD. Efﬁcient hepatic
glycogen synthesis in refeeding rats requires continued carbon ﬂow
through the gluconeogenic pathway. J Biol Chem 1984;259:6958–6963
38. Sugden MC, Watts DI, Palmer TN, Myles DD. Direction of carbon ﬂux in
starvation and after refeeding: in vitro and in vivo effects of 3-mercaptopi-
colinate. Biochem Int 1983;7:329–337
39. Taylor R, Magnusson I, Rothman DL, Cline GW, Caumo A, Cobelli C,
Shulman GI. Direct assessment of liver glycogen storage by 13C nuclear
magnetic resonance spectroscopy and regulation of glucose homeostasis
after a mixed meal in normal subjects. J Clin Invest 1996;97:126–132
40. Choi IY, Wu C, Okar DA, Lange AJ, Gruetter R. Elucidation of the role of
fructose 2,6-bisphosphate in the regulation of glucose ﬂuxes in mice using
in vivo (13)C NMR measurements of hepatic carbohydrate metabolism.
Eur J Biochem 2002;269:4418–4426
41. Halimi S, Assimacopoulos-Jeannet F, Terrettaz J, Jeanrenaud B. Differen-
tial effect of steady-state hyperinsulinaemia and hyperglycaemia on he-
patic glycogenolysis and glycolysis in rats. Diabetologia 1987;30:268–272
42. Terrettaz J, Assimacopoulos-Jeannet F, Jeanrenaud B. Inhibition of he-
patic glucose production by insulin in vivo in rats: contribution of
glycolysis. Am J Physiol 1986;250:E346–E351
43. Le Lay J, Tuteja G, White P, Dhir R, Ahima R, Kaestner KH. CRTC2
(TORC2) contributes to the transcriptional response to fasting in the liver
but is not required for the maintenance of glucose homeostasis. Cell Metab
2009;10:55–62
44. Hendrick GK, Frizzell RT, Williams PE, Cherrington AD. Effect of hyper-
glucagonemia on hepatic glycogenolysis and gluconeogenesis after a
prolonged fast. Am J Physiol 1990;258:E841–E849
45. Rothman DL, Magnusson I, Katz LD, Shulman RG, Shulman GI. Quantita-
tion of hepatic glycogenolysis and gluconeogenesis in fasting humans with
13C NMR. Science 1991;254:573–576
46. Blackshear PJ, Holloway PA, Aberti KG. The effects of inhibition of
gluconeogenesis on ketogenesis in starved and diabetic rats. Biochem J
1975;148:353–362
47. DiTullio NW, Berkoff CE, Blank B, Kostos V, Stack EJ, Saunders HL.
3-mercaptopicolinic acid, an inhibitor of gluconeogenesis. Biochem J
1974;138:387–394
48. Ferre P, Pegorier JP, Girard J. The effects of inhibition of gluconeogenesis
in suckling newborn rats. Biochem J 1977;162:209–212
49. Burgess SC, He T, Yan Z, Lindner J, Sherry AD, Malloy CR, Browning JD,
Magnuson MA. Cytosolic phosphoenolpyruvate carboxykinase does not
solely control the rate of hepatic gluconeogenesis in the intact mouse liver.
Cell Metab 2007;5:313–320
50. Defronzo RA. Banting Lecture: From the triumvirate to the ominous octet:
a new paradigm for the treatment of type 2 diabetes mellitus. Diabetes
2009;58:773–795
51. Korsheninnikova E, Voshol PJ, Baan B, van der Zon GC, Havekes LM,
Romijn JA, Maassen JA, Ouwens DM. Dynamics of insulin signalling in
liver during hyperinsulinemic euglycaemic clamp conditions in vivo and
the effects of high-fat feeding in male mice. Arch Physiol Biochem
2007;113:173–185
52. Ropelle ER, Pauli JR, Cintra DE, Frederico MJ, de Pinho RA, Velloso LA,
De Souza CT. Acute exercise modulates the Foxo1/PGC-1alpha pathway in
the liver of diet-induced obesity rats. J Physiol 2009;587:2069–2076
53. Samuel VT, Beddow SA, Iwasaki T, Zhang XM, Chu X, Still CD, Gerhard GS,
Shulman GI. Fasting hyperglycemia is not associated with increased
expression of PEPCK or G6Pc in patients with type 2 diabetes. Proc Natl
Acad SciUSA2009;106:12121–12126
C.J. RAMNANAN AND ASSOCIATES
diabetes.diabetesjournals.org DIABETES, VOL. 59, JUNE 2010 1311